Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

Publisher： Karger

E-ISSN： 1423-0100|53|3|146-153

ISSN： 0300-5526

Source： Intervirology, Vol.53, Iss.3, 2010-01, pp. : 146-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C

By                                                  

International Journal of Molecular Medicine, Vol. 30, Iss. 5, 2012-01 ,pp. : 1048-1052

Spandidos Publications

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eicosapentaenoic Acid Could Permit Maintenance of the Original Ribavirin Dose in Chronic Hepatitis C Virus Patients during the First 12 Weeks of Combination Therapy with Pegylated Interferon-α and Ribavirin

By  

Intervirology, Vol. 50, Iss. 6, 2008-02 ,pp. : 439-446

Karger

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 270-9139, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

By  

HEPATOLOGY, Vol. 62, Iss. 4, 2015-10 ,pp. : 1013-1023

John Wiley & Sons Inc

Access to resources Recommend Favorite